Well, one would first have to believe that the fair value for this stock today / 3-4 months from now is below the warrant strike price of $3.20, which I certainly do not.
What’s changed negatively with the company itself between uplist and today to warrant a $1.75 share price? Yes, dilution, but also for another $18M net in cash, with several US institutional healthcare investors as part of our shareholder base.
Why is our current market cap below our cash on hand? Manipulation of our stock is factual, anyone can see that.
The company continues to hit milestones. They continue to move closer than ever to the major catalysts “design freeze, fda, CE, etc.” Although, note that the confidence build will be done this December 2018, which means SPORT is basically design frozen. Anyway, there is much to be excited about, as well as much to be bummed about. Furthermore, no one even considers or talks about any positive surprises and what that would do to our share price (google Mazor and Medtronic partnership for a glimpse at what that could do, and it’s as definite a possibility as much as this stock going below $1).
I could list more, and maybe I will in time, but I got to get some work done. I will say I’m still very confident in the eventual outcome of our investment and SPORT clinically. Best of luck to you and everyone invested here!
News 
Market Data 
Discover 
